Question
What will SPCX's closing share price (USD) be 30 calendar days after the IPO insider lockup expires?
Update August 6, 2026: The median was slightly lowered to reflect the expected downward pressure of the final December lockup supply cliff relative to earlier late-2026 milestones, while tail outcomes were broadened to account for the extreme binary potential of passive index inflows colliding with insider selling.
Current Dynamics and the AI Capex Shock SPCX has seen extreme volatility since its June 2026 IPO at $135. After peaking near $225, the stock has broken downward to trade around $108 2 sources. The primary catalyst for this collapse was the August 4 Q2 earnings report. Although revenue beat expectations at $7.81B (+92% YoY), the market aggressively penalized the massive scale of the company's AI compute buildout 3 sources. Q2 capex exploded to $18.4B (bringing H1 to $28.5B, a 4x YoY increase), prompting sell-side models to project severe free-cash-flow deficits and escalating debt 3 sources. This pivot from a straightforward top-line growth story to a highly capital-intensive AI infrastructure play has profoundly altered the near-term valuation anchor.
Lockup Mechanics and Supply Flow The December 8 expiry is often cited as a massive supply cliff, but the actual mechanics tell a different story. The lockup is highly staggered, with a ~911.5M share tranche hitting August 6, followed by bi-weekly releases through October, and another large tranche tied to Q3 earnings 3 sources. By the time the final 180-day backstop arrives on December 8, the market will have already absorbed multiple waves of insider supply. Furthermore, Elon Musk's ~42% stake remains locked until June 2027, creating a persistent, longer-term overhang rather than an acute January crisis 2 sources. Because academic base rates for lockup expirations point to modest price effects (averaging ~-1.5%) nytimes.com, the supply drip acts as a steady headwind capping rallies rather than a catalyst for a sudden single-day crash.
Offsetting Demand and Short Squeeze Risk Working against this mechanical supply are two potent forces: passive index demand and extreme short positioning. SPCX was fast-tracked into the Nasdaq-100 and other major indices; as its float expands with each lockup release, its float-adjusted index weight will mechanically rise 2 sources. The December rebalance alone could force roughly $20B of passive buying right around our January target window bradmunchen.substack.com. Concurrently, short interest is hovering around 30-35% of the float, with nearly half the float out on loan 2 sources. With options pricing extreme volatility and sell-side consensus targets still well above spot businessinsider.com, any lighter-than-feared insider selling or a fundamental validation of the AI spend could trigger a violent squeeze.
Valuation Tails and Key Catalysts The median estimate of $103.70 sits slightly below current spot, reflecting the balance of negative momentum, the ongoing supply drip, and AI-capex financing risk, which offset robust top-line growth and passive inflows. The most critical feature of this assessment, however, is the extreme width of the tails. With implied volatility running near or above 100% and options pricing massive earnings moves 3 sources, a 5-month horizon dictates severe dispersion. The downside (p10 of $61.0) captures a scenario where the AI trade fractures and heavy insider liquidation meets an exhausted buyer base. Conversely, the right tail (p90 of $171.3) accounts for a scenario where the early November Q3 report validates the $100B revenue run-rate guide fool.com, passive index flows overwhelm sellers, and a short squeeze forcibly re-rates the stock back above its IPO price.
The median was slightly lowered to reflect the expected downward pressure of the final December lockup supply cliff relative to earlier late-2026 milestones, while tail outcomes were broadened to account for the extreme binary potential of passive index inflows colliding with insider selling.
Ask a followup
Sign in to run · $20 free credit, no card · every claim cited